Result card

  • ECO5: What are the incremental effects of uPA/PAI-1 (Femtelle), OncotypeDx™ or MammaPrint® relative to standard clinical practice?
English

What are the incremental effects of uPA/PAI-1 (Femtelle), OncotypeDx™ or MammaPrint® relative to standard clinical practice?

Authors: Isaura Vieira, Mirella Corio, Maria Rosaria Perrini, Matteo Ruggeri

Internal reviewers: Hanan Bell, Marco Oradei, Michelle O'Neill, Patricia Harrington, Kristi Liiv

Analysis of selected studies extracted from the basic literature search.

According to the EFF domain, there is insufficient high quality evidence to assess the effectiveness of the intervention. Without this information, it is not possible to calculate the incremental effects.

More information on this topic can be found in result cards RC-EFF9, RC-EFF10, RC-EFF11, RC-EFF13.

Further development of high quality evidence from RCTs on effectiveness is needed as discussed in the EFF domain.

Critical
Completely
Vieira I et al. Result Card ECO5 In: Vieira I et al. Costs and economic evaluation In: Jefferson T, Vicari N, Raatz H [eds.]. Prognostic tests for breast cancer recurrence (uPA/PAI-1 [FEMTELLE], MammaPrint, Oncotype DX ) [Core HTA], Agenzia nationale per i servizi sanitari regionali (age.na.s), Italy ; 2013. [cited 2 December 2022]. Available from: http://corehta.info/ViewCover.aspx?id=113